Which Pneumococcal Vaccine for Adults with COPD?

In a small study, serologic responses were generally better with the 7-valent protein-conjugate vaccine than with the currently approved 23-valent polysaccharide vaccine.

Because of the morbidity and mortality of pneumococcal infection among adults with chronic obstructive pulmonary disease (COPD), the CDC recommends that such individuals receive the 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, the immunogenicity and protective efficacy of PPSV23 in this population remain uncertain. Although not currently licensed for adults, the 7-valent protein-conjugate pneumococcal vaccine (PCV7) produces a potent immune response and reduces the incidence of invasive pneumococcal disease in children.

Now, in a multicenter, randomized, open-label trial, researchers have compared the safety and immunogenicity of these two vaccines in adults with moderate-to-severe COPD. Fifty-seven participants received …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Which Pneumococcal Vaccine for Adults with COPD?

Topics

Reviewing Author